We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Halozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9%
Halozyme Therapeutics, Inc. (HALO - Free Report) was a big mover last session, as the company saw its shares rise almost 8% on the day. The stock rallied after Piper Jaffray raised its price target on the stock from $15 to $18 on "increased conviction" in the long-term value of the San Diego-based biotech's company’s products, after an investor meeting with Halozyme’s management. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.42 to $11.10 in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Halozyme Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
HALOZYME THERA Price
HALOZYME THERA Price | HALOZYME THERA Quote
A better-ranked Medical/Biomedical-Gene stock is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is HALO going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>